Publications by authors named "Bjoern Harder"
Background: To compare an intravitreal high-dose injection of triamcinolone acetonide with an intravitreal injection of bevacizumab for the treatment of progressive exudative age-related macular degeneration (AMD).
Method: The comparative nonrandomized retrospective clinical interventional study included 305 patients with progressive AMD, divided into a bevacizumab group of 36 patients (1.5 mg bevacizumab) and a triamcinolone group of 269 patients (about 20 mg triamcinolone).
Ophthalmodynamometric differences between ischemic vs nonischemic retinal vein occlusion.
Am J Ophthalmol
January 2007
Purpose: To estimate the central retinal vein pressure in patients with ischemic vs nonischemic central retinal vein occlusion (CRVO).
Design: Prospective clinical observational comparative study.
Methods: The study included 28 patients with CRVO, either of the ischemic type (n = 7) or the nonischemic type (n = 21).
Objective: The aim of this study was to compare the visual acuity change after an intravitreal high-dose injection of triamcinolone acetonide (TA) in various types of exudative age-related macular degeneration (AMD).
Participants: The interventional comparative case series study included 142 patients (146 eyes) with progressive exudative AMD differentiated into the occult type (n = 78; 53.4%), minimal classic type (n = 45; 30.
Background: Intravitreal triamcinolone acetonide has been discussed as treatment for exudative age-related macular degeneration (AMD).
Objectives: To give an updated report on repeated intravitreal injections of triamcinolone acetonide (IVTA) for the treatment of exudative AMD.
Methods: The case-series study included 24 patients (24 eyes) with progressive exudative AMD who had shown an increase in, or stabilization of, visual acuity after a first IVTA, and who eventually experienced a deterioration of visual acuity.
Purpose: The aim of this study is to report on the clinical course of a patient showing markedly increased intraocular pressure (IOP) caused by intravitreal triamcinolone acetonide.
Methods: A 33-year-old patient received an intravitreal injection of approximately 20 mg of triamcinolone acetonide (TA) as treatment of otherwise therapy-resistant uveitis. She experienced an IOP rise to values over 40 mmHg for a period for more than 3 months, despite maximal antiglaucomatous medical therapy.
Purpose: The aim of this study was to examine the visual outcome of patients receiving an intravitreal injection of triamcinolone acetonide (TA) as treatment of diffuse diabetic macular edema (DDME).
Methods: This prospective, placebo-controlled, randomized, clinical interventional study included 40 eyes (38 patients) with DDME, with 28 (70%) eyes randomized to treatment and 12 (30%) eyes randomized to receive a placebo injection. Thirty-six (36) (90%) eyes completed the 3-month study visit, and 32 (80%) eyes completed the 6-month study visit.
Intravitreal triamcinolone acetonide for treatment of acute nonarteritic anterior ischemic optic neuropathy.
Graefes Arch Clin Exp Ophthalmol
May 2007
Purpose: To report on the use of intravitreal triamcinolone acetonide as treatment for nonarteritic anterior ischemic optic neuropathy (NAION).
Methods: The interventional clinical case series included three patients with acute NAION who received an intravitreal injection of about 20 mg triamcinolone acetonide.
Results: At the end of follow-up at 3 months, 3.
Purpose: To evaluate the rate of infectious and noninfectious endophthalmitis after intravitreal injection of a high-dosage of triamcinolone acetonide.
Design: Clinical interventional case-series study.
Methods: The study included 1135 intravitreal injections of approximately 20 mg triamcinolone performed for 915 eyes with diabetic macular edema (n = 257), exudative age-related macular degeneration (n = 561), retinal vein occlusions (n = 82), and other reasons.